Orion Transforms its Clinical Trials with Medidata
Global pharmaceutical company expands use of Medidata Rave Clinical CloudTM to spur growth and innovation
- Agreement builds on long-standing relationship since 2006
- Unified platform approach creates a single source of truth for greater efficiency and accelerated trials
- Self-sufficient study teams use intuitive, modern interface to quickly and efficiently set up trial protocols
NEW YORK – June 25, 2019 – Medidata (NASDAQ: MDSO) today announced that global pharmaceutical company Orion will consolidate all clinical trials on the Medidata Rave Clinical CloudTM and expand its use of trial management solutions to support growth of its R&D pipeline.
By unifying all required capabilities to deliver a successful clinical trial, the Rave Clinical Cloud has become the platform of choice. It creates a single source of truth for all study-related data. This data-driven approach to clinical study conduct breaks down silos and enables study teams to reuse study data when needed.
This expansion, which includes Medidata Rave RTSM, empowers Orion to randomize patients instantly in a single platform. The company can now optimize operational execution, reduce the number of clinical systems, decrease data entry and maintenance burdens, and increase the speed of its trials. With intelligent oversight across its trial planning, conduct, and management activities, Orion will make better informed decisions and optimize outcomes.
“When selecting our platform we needed confidence that it could support big changes, both in our business and the wider industry,” said Olavi Kikku, director R&D data science & analytics at Orion Corporation. “Years of partnership with Medidata convinced us that they are the best fit. Their constant innovation and product roadmap aligned with our own ambitions for evolving toward the future of clinical trials.”
“Orion continues to pioneer digital transformation in clinical development,” commented Glen de Vries, president and cofounder, Medidata. “The company understands the power of leveraging advanced solutions on a unified platform to reduce risk, accelerate time to market and improve outcomes. We look forward to our ongoing partnership and the future innovation it will bring.”
About Orion Corporation
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion invents, develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2018 amounted to EUR 977 million and the company had about 3,200 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki. For more information, go to www.orion.fi/en
Medidata is leading the digital transformation of life science, with the world's most used platform for clinical development, commercial, and real-world data. Powered by artificial intelligence and delivered by top-ranked industry experts, Medidata helps pharmaceutical, biotech, medical device companies, and academic researchers accelerate value, minimize risk and optimize outcomes. Medidata and its companies, Acorn AI and SHYFT, serve 1,300 customers and partners worldwide and empower more than 150,000 certified users every day to create hope for millions of patients. Discover the future of life science: www.medidata.com
Investor: Betsy Frank, +1 917-522-4620, email@example.com
Media: Erik Snider, +1 646-362-2997, firstname.lastname@example.org